

21 November 2018

UBS AG, Australia Branch
ABN 47 088 129 613
AFSL No: 231087
GPO Box 4151
Sydney NSW 2001
Australia
Tel. 612-9324 2000

Equity Operations Level 16 Chifley Tower 2 Chifley Square Sydney NSW 2000 Tel. 61 2-9324 2000 Fax 61 2-9324 2669

www.ubs.com/instalments

Participating Organisation of the Australian Stock Exchange

FOR IMMEDIATE RELEASE TO THE MARKET

The Warrant Administration Manager ASX Structured Products Level 6, 20 Bridge Street Sydney NSW 2000

Wesfarmers Limited Instalments – Adjustments in respect of Wesfarmers Limited Demerger

UBS AG Australia Branch ("UBS") is the issuer of the below series of instalment warrants (collectively known as "WES Instalments" in this announcement) over fully paid ordinary shares of Wesfarmers Limited ("WES"). Each WES Instalment has been offered under the corresponding Product Disclosure Statements ("PDS") listed in the table below.

Series	Date of PDS or Master PDS	Date of SPDS or Term Sheet	
WESISH	16-Feb-11	27-Mar-18	
WESISK	17-Oct-14	31-May-16	
WESISV	17-Oct-14	27-Mar-18	
WESISW	17-Oct-14	16-May-18	
WESISX	17-Oct-14	8-Jun-18	
WESSSA	25-Sep-14	17-Oct-14	
WESSSE	16-Oct-15	31-May-16	
WESSSK	23-May-11	29-May-18	
WESSSL	16-Oct-15	16-Oct-15	
WESSSZ	16-Oct-15	11-Apr-16	

This announcement concerns adjustments which UBS intends to make to the terms of the WES Instalments as a result of the announcement by WES of the demerger of Coles Group Limited ("Coles") from WES ("WES Demerger") by a scheme of arrangement and capital reduction. This demerger involves an in-specie distribution of 1 Coles ordinary share for every 1 existing WES share held on 22 November 2018. Full details of the WES Demerger are set out in the announcement by WES dated 5 October 2018 (which can be found at www.asx.com.au).

Further to UBS's announcement dated 20 November 2018, the Loan Amount for the WES Instalments will be reduced by the value of the new Coles ordinary shares per WES ordinary share on the first day of deferred settlement trading ("Entitlement Value") and an Interest Refund amount. The Capped Level (if applicable) will be adjusted accordingly.

The Entitlement Value per WES ordinary share has been calculated as follows: Entitlement Value = $1/1 \times (VWAP \text{ of new Coles ordinary shares})$ = $1/1 \times 12.8806

= \$12.8806

The New Loan Amounts and Capped Levels (if applicable) have been calculated as follows:

• New Loan Amount = Old Loan Amount - Entitlement Value - Interest Refund

Warrant Code	Old Loan Amount / Completion Payment	Entitlement Value	Interest Refund	New Loan Amount / Completion Payment	New Capped Level (if applicable)
WESISH	\$41.8000	\$12.8806	\$0.1324	\$28.7870	\$37.3194
WESISK	\$24.9755	\$12.8806	\$0.2080	\$11.8869	N/A
WESISV	\$41.5500	\$12.8806	\$0.1324	\$28.5370	N/A
WESISW	\$24.2000	\$12.8806	\$0.2080	\$11.1114	N/A
WESISX	\$46.7500	\$12.8806	\$0.1324	\$33.7370	N/A
WESSSA	\$21.2841	\$12.8806	\$0.2080	\$8.1955	N/A
WESSSE	\$24.3710	\$12.8806	\$0.2080	\$11.2824	N/A
WESSSK	\$50.4225	\$12.8806	\$0.2301	\$37.3118	\$46.6194
WESSSL	\$22.0263	\$12.8806	\$0.2080	\$8.9377	N/A
WESSSZ	\$24.3778	\$12.8806	\$0.2080	\$11.2892	N/A

The WES Instalments are expected to recommence trading from Thursday 22 November 2018 with the new Loan Amounts and Capped Levels (if applicable). Unless otherwise stated, all terms used in this letter have the same meaning as in the PDS.

If you have any questions regarding this announcement please contact your financial adviser or call the UBS Warrant Sales Desk on 1800 633 100.

Yours sincerely,

UBS AG, Australia Branch

UBS AG Australia Branch

Idie (A.

Andrew Lockhart Director **UBS AG Australia Branch**

Scott Hanlon Executive Director

Important Notice

This letter has no regard to the specific investment objectives, financial situation or particular needs of the specific recipient and does not purport to give any financial, taxation or legal advice. UBS makes no representation as to the accuracy or otherwise of any interpretation of law, or any conclusion based on that interpretation that may be contained in this letter. Recipients of this letter should obtain independent advice on the tax, legal and financial implications of the corporate action referred to in this letter. This letter is published solely for informational purposes and is not to be construed as a solicitation, recommendation or offer to buy or sell any related financial instruments. The contents of this letter should not be regarded by recipients as a substitute for the exercise of their own judgement. UBS accepts no liability whatsoever for any loss or damage of any kind arising out of the use of all or any part of the letter.